FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2785572018> ?p ?o ?g. }

• W2785572018 endingPage "S52" @default.
• W2785572018 startingPage "S41" @default.
• W2785572018 abstract "BackgroundThe present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biologic therapies.AimsTo review, from an infectious diseases perspective, the safety profile of therapies targeting cell surface receptors and associated signaling pathways among cancer patients and to suggest preventive recommendations.SourcesComputer-based Medline searches with MeSH terms pertaining to each agent or therapeutic family.ContentVascular endothelial growth factor (VEGF)-targeted agents (bevacizumab and aflibercept) are associated with a meaningful increase in the risk of infection, likely due to drug-induced neutropaenia, although no clear benefit is expected from the universal use of anti-infective prophylaxis. VEGF tyrosine kinase inhibitors (i.e. sorafenib or sunitinib) do not seem to significantly affect host's susceptibility to infection, and universal anti-infective prophylaxis is not recommended either. Anti–epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab or panitumumab) induce neutropaenia and secondary skin and soft tissue infection in cases of severe papulopustular rash. Systemic antibiotics (doxycycline or minocycline) should be administered to prevent the latter complication, whereas no recommendation can be established on the benefit from antiviral, antifungal or anti-Pneumocystis prophylaxis. A lower risk of infection is reported for anti-ErbB2/HER2 monoclonal antibodies (trastuzumab and pertuzumab) and ErbB receptor tyrosine kinase inhibitors (including dual-EGFR/ErbB2 inhibitors such as lapatinib or neratinib) compared to conventional chemotherapy, presumably as a result of the decreased occurrence of drug-induced neutropaenia.ImplicationsWith the exception of VEGF-targeted agents, the overall risk of infection associated with the reviewed therapies seems to be low." @default.
• W2785572018 created "2018-02-23" @default.
• W2785572018 creator A5016258231 @default.
• W2785572018 creator A5024995771 @default.
• W2785572018 creator A5040173904 @default.
• W2785572018 creator A5049068419 @default.
• W2785572018 creator A5059519339 @default.
• W2785572018 date "2018-06-01" @default.
• W2785572018 modified "2023-10-16" @default.
• W2785572018 title "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)" @default.
• W2785572018 cites W1539571840 @default.
• W2785572018 cites W1673015956 @default.
• W2785572018 cites W1816702532 @default.
• W2785572018 cites W1896890211 @default.
• W2785572018 cites W1939417476 @default.
• W2785572018 cites W1940111737 @default.
• W2785572018 cites W1964424495 @default.
• W2785572018 cites W1966201413 @default.
• W2785572018 cites W1967394241 @default.
• W2785572018 cites W1968430623 @default.
• W2785572018 cites W1972433976 @default.
• W2785572018 cites W1977614360 @default.
• W2785572018 cites W1979439341 @default.
• W2785572018 cites W1980725734 @default.
• W2785572018 cites W1990542180 @default.
• W2785572018 cites W1992878563 @default.
• W2785572018 cites W2000798782 @default.
• W2785572018 cites W2005699818 @default.
• W2785572018 cites W2006561878 @default.
• W2785572018 cites W2014129405 @default.
• W2785572018 cites W2015918488 @default.
• W2785572018 cites W2016710415 @default.
• W2785572018 cites W2019236425 @default.
• W2785572018 cites W2019303762 @default.
• W2785572018 cites W2028696387 @default.
• W2785572018 cites W2031000957 @default.
• W2785572018 cites W2040089666 @default.
• W2785572018 cites W2040830854 @default.
• W2785572018 cites W2043125222 @default.
• W2785572018 cites W2043696829 @default.
• W2785572018 cites W2047883444 @default.
• W2785572018 cites W2047963211 @default.
• W2785572018 cites W2048563089 @default.
• W2785572018 cites W2050037358 @default.
• W2785572018 cites W2054050668 @default.
• W2785572018 cites W2054154232 @default.
• W2785572018 cites W2074270635 @default.
• W2785572018 cites W2074987421 @default.
• W2785572018 cites W2078454159 @default.
• W2785572018 cites W2079953288 @default.
• W2785572018 cites W2080115932 @default.
• W2785572018 cites W2085633477 @default.
• W2785572018 cites W2088935000 @default.
• W2785572018 cites W2089996625 @default.
• W2785572018 cites W2090432882 @default.
• W2785572018 cites W2092246935 @default.
• W2785572018 cites W2095201384 @default.
• W2785572018 cites W2095618958 @default.
• W2785572018 cites W2096198395 @default.
• W2785572018 cites W2098354753 @default.
• W2785572018 cites W2098775844 @default.
• W2785572018 cites W2100669312 @default.
• W2785572018 cites W2100756525 @default.
• W2785572018 cites W2102147859 @default.
• W2785572018 cites W2103563357 @default.
• W2785572018 cites W2104759721 @default.
• W2785572018 cites W2105261759 @default.
• W2785572018 cites W2108923852 @default.
• W2785572018 cites W2109823414 @default.
• W2785572018 cites W2111237964 @default.
• W2785572018 cites W2111662961 @default.
• W2785572018 cites W2112845420 @default.
• W2785572018 cites W2113122060 @default.
• W2785572018 cites W2113257521 @default.
• W2785572018 cites W2114610003 @default.
• W2785572018 cites W2115330744 @default.
• W2785572018 cites W2115735904 @default.
• W2785572018 cites W2118216472 @default.
• W2785572018 cites W2120661754 @default.
• W2785572018 cites W2121847974 @default.
• W2785572018 cites W2123965006 @default.
• W2785572018 cites W2124267708 @default.
• W2785572018 cites W2124606227 @default.
• W2785572018 cites W2125245491 @default.
• W2785572018 cites W2125447919 @default.
• W2785572018 cites W2125733496 @default.
• W2785572018 cites W2126275851 @default.
• W2785572018 cites W2129360604 @default.
• W2785572018 cites W2132157071 @default.
• W2785572018 cites W2133105825 @default.
• W2785572018 cites W2135947389 @default.
• W2785572018 cites W2136110110 @default.
• W2785572018 cites W2136601558 @default.
• W2785572018 cites W2137043950 @default.
• W2785572018 cites W2138297714 @default.
• W2785572018 cites W2138941169 @default.
• W2785572018 cites W2139135964 @default.
• W2785572018 cites W2139236349 @default.

• next